{"classes":[{"categories":[{"measurements":[{"comment":"Median overall survival was not reached for patients in the BiRd arm (95% CI: 906-NA).","groupId":"OG000","lowerLimit":"906","upperLimit":"NA","value":"NA"},{"comment":"Participants were still alive at the time of study closure.","groupId":"OG001","lowerLimit":"821","upperLimit":"NA","value":"1014"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"5"}],"units":"Participants"}],"description":"Survival following treatment to the date of death of subjects on BiRd regimen as compared to Rd.","dispersionType":"95% Confidence Interval","groups":[{"description":"Subjects on the BiRD arm will receive clarithromycin, lenalidomide, and dexamethasone in 28-day cycles.\n\nClarithromycin: 500mg PO twice daily on days 1-28 for a 28-day cycle.\n\nLenalidomide: 25 mg PO days 1-21 followed by a 7 day rest period for each 28-day cycle\n\nDexamethasone: 20 mg PO on Days 1, 8, 15, and 22 for each cycle for subjects 75 years and younger.","id":"OG000","title":"BiRD Treatment Regimen"},{"description":"Subjects on the Rd arm will receive lenalidomide and dexamethasone in 28-day cycles.\n\nLenalidomide: 25 mg PO days 1-21 followed by a 7 day rest period for each 28-day cycle\n\nDexamethasone: 20 mg PO on Days 1, 8, 15, and 22 for each cycle for subjects 75 years and younger.","id":"OG001","title":"Rd Treatment Regimen"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"4 years","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"days"}